REPROCELL Showcases Human-Relevant Respiratory Research Model
- kelseygarbutt
- Oct 14
- 1 min read
REPROCELL, a life sciences company based at NETPark, is spotlighting its Precision-Cut Lung Slice (PCLS) assay — a powerful tool for respiratory drug development that maintains the structure and cell interactions of native lung tissue.
Using both healthy and diseased samples, including COPD and asthma, the PCLS assay enables researchers to assess drug efficacy, toxicity, and mechanisms of action in a physiologically relevant, human-based model. Cultured for up to seven days, the slices support a wide range of applications, from biomarker analysis to imaging and histology.
This innovative platform is helping accelerate respiratory research while offering a more ethical and accurate alternative to traditional models. To learn more, REPROCELL has published a detailed article available here.
As part of the NETPark community, REPROCELL continues to advance human-focused biomedical research. NETPark is home to pioneering companies working at the forefront of science and technology, driving innovation with real-world impact.
